Printer Friendly

DU PONT MERCK EXECUTIVE JOINS SYMPHONY PHARMACEUTICALS

 PHILADELPHIA, Aug. 19 /PRNewswire/ -- Symphony Pharmaceuticals, Inc. today announced it has appointed Saul Cherkofsky, Ph.D., as vice president, pharmaceutical development. Dr. Cherkofsky brings to Symphony more than 22 years experience in medicinal chemistry and pharmaceutical development at Du Pont and Du Pont Merck.
 "Saul will be responsible for all our pharmaceutical and pre- clinical development," said Maria-Luisa Maccecchini, Ph.D., Symphony founder and CEO. "Saul's pharmaceutical background and scientific leadership will be critical in this capacity."
 Prior to joining Symphony, Dr. Cherkofsky was an executive director at Du Pont Merck where he was responsible for a group of 400 people located at five sites. His responsibilities included guiding all non- clinical development areas of INDs and NDAs.
 "I am pleased to have the opportunity to combine my pharmaceutical development knowledge and experience with Symphony's exciting research and development programs," said Dr. Cherkofsky. "Together we can play an important role in bringing new drugs to people who suffer from neurological and psychosomatic diseases."
 Dr. Cherkofsky has a Ph.D. in organic chemistry from Harvard University and a B.S. in chemistry from Massachusetts Institute of Technology. He is the author of 22 patents and numerous publications.
 Symphony, founded in 1992, is private biopharmaceutical company focusing on the discovery and development of novel drugs to regulate the flow of electricity through ion channels in the brain. The company has targeted its initial drug development efforts on stroke, trauma, depression and addiction. Symphony's technology can also be applied to anxiety, epilepsy, memory loss and learning disabilities as well as Huntington's, Alzheimer's and Parkinson's diseases.
 -0- 8/19/93
 /CONTACT: Maria-Luisa Maccecchini, Ph.D., chief executive officer of Symphony Pharmaceuticals, Inc., 215-640-4870, or Anthony J. Russo of Noonan/Russo Communications, 212-696-4455/


CO: Symphony Pharmaceuticals, Inc. ST: Pennsylvania IN: MTC SU: PER

DH-SM -- NY011 -- 4206 08/19/93 09:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 19, 1993
Words:307
Previous Article:ECOGEN SIGNS AGREEMENTS WITH TOP GERMAN UNIVERSITY AND EUROPEAN DISTRIBUTION PARTNER
Next Article:KASH N' KARRY FOOD STORE EXTENDS TENDER OFFER
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters